

ASX / MEDIA ANNOUNCEMENT

18 June 2020

Settlement with Former CEO

Respiri Limited (ASX:RSH) ("Respiri" or the "Company"), an eHealth SaaS Company supporting respiratory health management, today announces a legal settlement with the former CEO of Respiri, Mr Mario Gattino.

Legal proceedings were commenced by Mr Gattino on 21 February 2020 in the Federal Court of Australia against each of Respiri and two former Directors of Respiri. The current Board of Directors were not part of the legal action.

The terms of the settlement remain confidential. However, Respiri in line with its previous ASX disclosure can confirm that the settlement comprises an immaterial cash payment in consideration of him agreeing to forfeit his entitlement to potential short term incentive payments and providing the Company and its current and former officers, directors, employees and agents with full releases in relation to the claims that were the subject of the current legal proceeding and all potential future claims. As part of the settlement we are pleased that Mr Gattino will also finalise and pay for the previously shareholder approved 1.125 million Respiri shares at prices of \$0.08 and \$0.10.

Additionally, Respiri has also acknowledged the vesting of 12 million unlisted options in accordance with the vesting conditions applicable to those options (as distinct from been related to the end of Mr Gattino's employment with the Company).

Mr Nicholas Smedley, Executive Chairman of Respiri Limited said "The agreed settlement shows Mr Gattino has placed significant value on the long term prospects of Respiri and its share price potential, rather than any cash settlement. This is acceptable to all parties and now allows them to move forward without the distraction that a legal dispute represents. The current Respiri Board, comprising myself and my two fellow Directors, are focussed on executing our group corporate strategy with senior management, as we continue to progress corporate partnerships and the necessary steps for our full commercial launch in late 2020."

Mr Gattino commented "I fully support the strategy and plans of the Company and the direction the current Board of Directors is setting for Respiri. As a shareholder of the Company, our interests in building shareholder value are aligned and I wish the Board and the Company all the best as they prepare for the launch of the innovative wheezo[®] platform, which has the potential to benefit a large number of asthma sufferers throughout the world in managing their disease more effectively."

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
 CEO & Managing Director
 Respiri Limited
 P: +61 408 462 873
 E: marjan@respiri.co

Mr Nicholas Smedley
 Executive Chairman
 Respiri Limited
 P: +61 447 074 160
 E: nicholas@respiri.co

This ASX announcement dated 18 June 2020 has been authorised for release by the Board of Directors of Respiri Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co